Science and Products
EAL®
EAL®The product is a multi-target tumor immune cell product, with over ten years of track record in clinical applications for cancer treatment. EAL®is a formulation derived from T cells activated and expanded from the patient's peripheral blood (patent name: Method and Culture System for Efficiently Expanding Activated Lymphocytes; patent number: ZL200710102854.0), with CD8+ cytotoxic T cells (marked by the CD3 molecule) as the main active ingredient. The activated autologous lymphocyte (AAL) therapy (EAL®is one example) has shown effectiveness in preventing postoperative recurrence of liver cancer in overseas clinical trials. The safety and efficacy of EAL®in treating tumors have been published in three SCI academic journal articles. EAL®is currently undergoing a Phase II clinical trial study for the indication of preventing postoperative recurrence of liver cancer.
The company has nearly 80 core technology patents in key steps such as cell preparation. Now it has established a pipeline of 10 + genes and cell products for different cancer species, covering gene modification/non-gene modification, multi-target/single target, with target indications covering solid tumors, blood tumors, virus infection and other related diseases. Research and development progress is at the international advanced level. The company has undertaken a number of scientific research projects, such as the National 863 Project, the National Nature Fund, the Ministry of Industry and Information Technology High-quality Development Project, the Beijing Science and Technology Innovation Fund, and the National Ministry of Science and Technology Major New Drug Creation.
As of June 2024, a total of five immune cell therapy products have entered clinical trials. Core Product EAL®It is an immune cell therapy product approved to enter the Phase II clinical trial of solid tumor treatment in China, and will be included in the list of CDE breakthrough treatment varieties in September 2023, which is expected to fill the gap of immune cell therapy in the field of solid tumors in China. At the same time, with aT19, RC19D2, CAR-T-19 injection and other three approved gene-modified cell drugs into clinical trials, and the perfect combination of two gene-modified product TCR-T-CMV and TCR-T-EBV for infection after hematopoietic stem cell transplantation, a rich research and development layout of immune cell therapy product pipelines in the field of hematological tumors has been formed.
Previous Page
Next Page